190 related articles for article (PubMed ID: 32911037)
1. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
[TBL] [Abstract][Full Text] [Related]
2. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
3. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
4. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
6. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
8. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
[TBL] [Abstract][Full Text] [Related]
9. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
[TBL] [Abstract][Full Text] [Related]
10. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
12. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
14. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
[TBL] [Abstract][Full Text] [Related]
15. Prescription Drugs Used in Insomnia.
Dujardin S; Pijpers A; Pevernagie D
Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
[TBL] [Abstract][Full Text] [Related]
16. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
17. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
[No Abstract] [Full Text] [Related]
18. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
[TBL] [Abstract][Full Text] [Related]
20. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
